Nov 05, 2021 05:59 PM (GMT+8) · EqualOcean
Financial Associated Press, November 5 - Fudan Zhangjiang announced that the company's fda018 antibody coupling agent for injection is carrying out phase I clinical research, and recently successfully completed the enrollment of the first subject. Fzj-003 capsule, namely oral Jak1 selective inhibitor (specification: 25mg, 50mg), was accepted as a clinical phase II trial for the treatment of moderate to severe atopic dermatitis.